文献速递脊柱关节炎

当常规诊疗并不常规:中轴型脊柱关节炎达标治疗策略试验中的方案违背与泛化性

When Usual Care Is Not So Usual: Protocol Violations and Generalizability in a Treat-to-Target Strategy Trial in Patients With Axial Spondyloarthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-07-14

本研究基于TICOSPA试验,评估达标治疗组方案违背的影响,并比较达标治疗组与常规诊疗组按2016年ASAS/EULAR推荐接受理想治疗的患者比例。160例患者入组,达标治疗组51.2%至少发生一次方案违背,但违背者与未违背者48周ASAS-HI改善比例相似;达标治疗组与常规诊疗组按推荐治疗的比例分别为63.9%与61.8%,常规诊疗组得到理想治疗部分解释了TICOSPA试验主要目标未达成。

要点

  • 达标治疗组51.2%患者至少发生一次方案违背,其中62.2%的违背导致维持或减少治疗。
  • 48周时达标治疗组违背者与未违背者ASAS-HI改善比例相似。
  • 前12周后按ASAS/EULAR推荐治疗的比例:达标治疗组63.9% vs 常规诊疗组61.8%。

核心结论

  • TICOSPA试验达标治疗组方案违背频繁,但未影响主要结局发生率;常规诊疗组得到理想治疗,部分解释了TICOSPA试验主要目标未达成。

研究设计与样本

  • 整群随机对照48周试验,纳入符合ASAS标准、ASDAS>2.1且未使用过生物制剂的axSpA患者。
  • 18个axSpA专家中心随机分配至达标治疗组(每4周访视)或常规诊疗组(每12周访视,由风湿科医生酌情决定治疗)。
  • 共160例患者启动试验,达标治疗组80例,常规诊疗组80例。

主要发现

  • 达标治疗组51.2%患者至少发生一次方案违背,其中62.2%的违背导致维持或减少治疗(违反方案)。
  • 48周时达标治疗组违背者与未违背者ASAS-HI改善比例相似。
  • 前12周后按ASAS/EULAR推荐治疗的患者比例:达标治疗组63.9% vs 常规诊疗组61.8%。

关键数值与推荐

  • ASAS/EULAR 2016推荐用于评估axSpA患者是否接受理想治疗。
  • ASDAS>2.1为入组标准之一。
  • ASAS-HI用于评估48周健康指数改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the impact of protocol violations in the treat-to-target group in the Tight Control in Spondyloarthritis (TICOSPA) trial and to compare the proportion of patients optimally treated according to the Assessment of Spondyloarthritis International Society (ASAS)/EULAR 2016 recommendations for patients with axial spondyloarthritis (axSpA) between the treat-to-target versus usual care (UC) arms. METHODS: This study was a cluster-randomized, controlled 48-week trial including patients with axSpA who fulfilled the ASAS criteria, had an Axial Spondyloarthritis Disease Activity Score >2.1, and were biologic disease-modifying antirheumatic drug naive. Eighteen axSpA expert centers were randomly allocated to one treatment arm: (a) treat-to-target prespecified management strategy (four-week visits), and (b) UC treatment decisions at the rheumatologist's discretion (12-week visits). Protocol violations in the treat-to-target arm and the fulfillment of the 2016 ASAS/EULAR recommendations in both arms were evaluated at every visit. ASAS Health Index (ASAS-HI) and disease activity outcomes at 48 weeks were compared between treat-to-target violators versus nonviolators. Patients treated according to the ASAS/EULAR recommendations were compared between both arms. RESULTS: A total of 160 patients initiated the trial (80 patients with treat to target; 80 patients with UC). In the treat-to-target arm, 51.2% patients violated the protocol at least once (62.2% of violations resulting in maintenance/reduction of treatment against protocol). After 48 weeks, treat-to-target violators versus nonviolators showed similar ratios of ASAS-HI improvement. The proportion of patients managed according to the ASAS/EULAR recommendations after the first 12 weeks were 63.9% versus 61.8% for the treat-to-target and UC arms, respectively. CONCLUSION: Protocol violations in the treat-to-target arm in the TICOSPA trial were frequent, although they did not have an impact on the rate of the primary outcome. The groups with UC was optimally treated, partly explaining the nonachievement of the primary objective in the TICOSPA trial.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. López-Medina C, van den Bosch F, van der Heijde D, et al. When Usual Care Is Not So Usual: Protocol Violations and Generalizability in a Treat-to-Target Strategy Trial in Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2024. PMID: 38924366. doi:10.1002/acr.25387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。